| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 01/20/2023 | 226.87% | Cantor Fitzgerald | $4 → $1.5 | Downgrades | Overweight → Neutral |
| 01/18/2023 | 226.87% | Lake Street | $5 → $1.5 | Maintains | Buy |
| 08/17/2022 | 989.56% | Lake Street | $7 → $5 | Maintains | Buy |
| 03/30/2021 | 1643.3% | Cantor Fitzgerald | → $8 | Initiates Coverage On | → Overweight |
| 11/05/2020 | 989.56% | Ascendiant Capital | → $5 | Initiates Coverage On | → Buy |
| 10/13/2020 | 989.56% | Lake Street | → $5 | Initiates Coverage On | → Buy |
| 06/28/2018 | 989.56% | Maxim Group | → $5 | Initiates Coverage On | → Buy |
What is the target price for PAVmed (PAVM)?
The latest price target for PAVmed (NASDAQ: PAVM) was reported by Cantor Fitzgerald on January 20, 2023. The analyst firm set a price target for $1.50 expecting PAVM to rise to within 12 months (a possible 226.87% upside). 3 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for PAVmed (PAVM)?
The latest analyst rating for PAVmed (NASDAQ: PAVM) was provided by Cantor Fitzgerald, and PAVmed downgraded their neutral rating.
When is the next analyst rating going to be posted or updated for PAVmed (PAVM)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of PAVmed, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for PAVmed was filed on January 20, 2023 so you should expect the next rating to be made available sometime around January 20, 2024.
Is the Analyst Rating PAVmed (PAVM) correct?
While ratings are subjective and will change, the latest PAVmed (PAVM) rating was a downgraded with a price target of $4.00 to $1.50. The current price PAVmed (PAVM) is trading at is $0.46, which is out of the analyst's predicted range.